Eisai News
Most Popular Eisai Story
Astex hammered after regulators diss Dacogen application
Shares of Astex Pharmaceuticals ($ASTX) got hammered yesterday after regulators turned a skeptical eye on Eisai's request for an expanded use of Dacogen, a leukemia-related drug the biotech licensed Read more...
Latest Headlines
- February 10, 2012
- February 8, 2012
- December 1, 2011
- September 7, 2011
- July 29, 2011
- April 14, 2011
- March 10, 2011
- January 31, 2011
- January 25, 2011
- December 22, 2010
- November 17, 2010
- November 16, 2010
- August 30, 2010
- August 24, 2010
- July 12, 2010
- July 1, 2010
- June 28, 2010
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
